Table 3. Top-ranked differentially methylated CpGs in African American patients according to features of more aggressive prostate cancer^a.

CpG ID	Chromosome	Gene	Gene location	Epigenetic location	Mean β group 1b	Mean β group 2c	Mean β difference ≥ 10% Δβ	Methylation status	FDR q-value ≤ 0.25	Total number of CpGs analyzed within the same gene and epigenetic location, and % that have a similar methylation profile to the top CpGd
Regional vs. local stage
cg11891579	5	EBF1	Body	island	0.58	0.41	0.18	hyper	0.03	7 (100%)
cg13295238	5	EBF1	Body	island	0.48	0.30	0.17	hyper	0.03	7 (100%)
High vs. low tumor aggressivenesse
cg18845377	7	intergenic	–	island	0.25	0.15	0.10	hyper	0.06	–

Abbreviations: PCa, prostate cancer; TSS1500, 201 to 1500 base pairs upstream of transcription start site; TSS200, 200 base pairs upstream of transcription start site; UTR, untranslated region

^aResults are from models that adjusted for age at diagnosis and study group and limited to CpGs with an FDR q-value ≤ 0.25 and mean methylation β value difference ≥ 0.10.

^bPatients with regional pathological stage or high tumor aggressiveness

^cPatients with local pathological stage or low tumor aggressiveness

^dThe % of CpGs in the same region as the top-ranked CpG that did not meet the criteria for differential methylation (FDR q-value ≤ 0.25 and mean methylation β value difference ≥ 0.10), but that had an increase or decrease in mean methylation level in the same direction as the top CpG for patients with regional vs. local stage.

^eComposite variable of tumor aggressiveness (High = one or more of the following: PCa recurrence or death; Gleason score (7=4+3 or 8-10); and/or regional stage)